InterPAD - DETAILS

CAPECITABINE, 154361-50-9, Xeloda, Capiibine, Capecitibine, Captabin, Capecytabine, 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine, Caxeta, Xabine, Capecitabine Sun, Capecitabine Teva, Capecitabine Medac, Capecitabine Accord, Ro 09-1978, capecitabina, capecitabinum, Capecitabin, Ecansya, Ro 09-1978/000, Pentyl (1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate, N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine, UNII-6804DJ8Z9U, Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate, 5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine, DTXSID3046451, CHEBI:31348, HSDB 7656, Ro-091978000, Cytidine, 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-, 6804DJ8Z9U, NSC-759853, (1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester, Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester, pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate, DTXCID1026451, RO-09-1978000, XELIRI COMPONENT CAPECITIBINE, Capecitabine [USAN:USP:INN:BAN], NSC 759853, Capecitabine [USAN], Ro-09-1978-000, Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate, CAPECITABINE (MART.), CAPECITABINE [MART.], pentyl 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-ylcarbamate, CAPECITABINE (USP-RS), CAPECITABINE [USP-RS], Cytidine, 5'-deoxy-5-fluoro-N-((pentyloxy)carbonyl)-, CAPECITABINE (EP MONOGRAPH), CAPECITABINE (USP IMPURITY), CAPECITABINE [EP MONOGRAPH], CAPECITABINE [USP IMPURITY], Capecitabine (USAN:USP:INN:BAN), CAPECITABINE (USP MONOGRAPH), CAPECITABINE [USP MONOGRAPH], Capecitabine (Xeloda), SMR002530052, Xeloda (TN), CAS-154361-50-9, R340, NSC712807, NCGC00164569-01, Pentyl (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate, Capecitabine 150mg, Capecitabine 500mg, RG-340, Capecitabine- Bio-X, Ro-09-1978, CAPECITABINE [MI], R-340, CAPECITABINE [INN], CAPECITABINE [JAN], CAPECITABINE [HSDB], Xelox component capecitabine, SCHEMBL8153, CAPECITABINE [VANDF], CHEMBL1773, MLS003915642, MLS004774137, pentyl N-{1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl}carbamate, CAPECITABINE [WHO-DD], Capecitabine (JAN/USP/INN), Capecitabine Tablets, 150 mg, Capecitabine Tablets, 500 mg, GTPL6799, CAPECITABINE [EMA EPAR], Capecitabine, analytical standard, Capecitabine, >=98% (HPLC), EX-A835, L01BC06, BCPP000300, CAPECITABINE [ORANGE BOOK], GLXC-03327, HY-B0016, Tox21_112198, s1156, AKOS015920130, Tox21_112198_1, AM84502, BCP9000483, BS-1000, CCG-264841, CS-0768, DB01101, NCGC00164569-02, NCGC00164569-05, NCGC00164569-11, BC164277, BP-58647, NS00000464, D01223, n4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine, AB01274776-01, AB01274776-02, AB01274776_04, 5'-deoxy-5-fluoro-N4-(pentyloxycarbonyl)cytidine, Q420207, SR-01000931255, 5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)-cytidine, J-700154, Q-200788, SR-01000931255-3, BRD-K61192372-001-08-9, Z1501480421, Capecitabine, European Pharmacopoeia (EP) Reference Standard, Capecitabine, United States Pharmacopeia (USP) Reference Standard, Capecitabine, Pharmaceutical Secondary Standard; Certified Reference Material, CARBAMIC ACID, (1-(5-DEOXY-.BETA.-D-RIBOFURANOSYL)-5-FLUORO-1,2-DIHYDRO-2-OXO-4-PYRIMIDINYL)-, PENTYL ESTER, PENTYL 1-(5-DEOXY-.BETA.-D-RIBOFURANOSYL)-5-FLUORO-1,2-DIHYDRO-2-OXO-4-PYRIMIDINECARBAMATE

No.	Title	Href
1	Hesperetin and Capecitabine Abate 1,2 Dimethylhydrazine-Induced Colon Carcinogenesis in Wistar Rats via Suppressing Oxidative Stress and Enhancing Antioxidant, Anti-Inflammatory and Apoptotic Actions. Life (Basel). 2023 Apr 11;13(4):984. doi: 10.3390/life13040984.	`Click`
2	γ-Tocotrienol suppresses growth and sensitises human colorectal tumours to capecitabine in a nude mouse xenograft model by down-regulating multiple molecules. Br J Cancer. 2016 Sep 27;115(7):814-24. doi: 10.1038/bjc.2016.257.	`Click`
3	First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway. Clin Cancer Res. 2012 Apr 15;18(8):2220-9. doi: 10.1158/1078-0432.CCR-11-2470.	`Click`
4	Dihydroartemisinin inhibits the development of colorectal cancer by GSK-3β/TCF7/MMP9 pathway and synergies with capecitabine. Cancer Lett. 2024 Feb 1;582:216596. doi: 10.1016/j.canlet.2023.216596.	`Click`

No.

Title

Href

Hesperetin and Capecitabine Abate 1,2 Dimethylhydrazine-Induced Colon Carcinogenesis in Wistar Rats via Suppressing Oxidative Stress and Enhancing Antioxidant, Anti-Inflammatory and Apoptotic Actions. Life (Basel). 2023 Apr 11;13(4):984. doi: 10.3390/life13040984.

Click

γ-Tocotrienol suppresses growth and sensitises human colorectal tumours to capecitabine in a nude mouse xenograft model by down-regulating multiple molecules. Br J Cancer. 2016 Sep 27;115(7):814-24. doi: 10.1038/bjc.2016.257.

Click

First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway. Clin Cancer Res. 2012 Apr 15;18(8):2220-9. doi: 10.1158/1078-0432.CCR-11-2470.

Click

Dihydroartemisinin inhibits the development of colorectal cancer by GSK-3β/TCF7/MMP9 pathway and synergies with capecitabine. Cancer Lett. 2024 Feb 1;582:216596. doi: 10.1016/j.canlet.2023.216596.

Click

Name	Capecitabine
PubChem CID	60953
Molecular Weight	359.35g/mol
Synonyms	CAPECITABINE, 154361-50-9, Xeloda, Capiibine, Capecitibine, Captabin, Capecytabine, 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine, Caxeta, Xabine, Capecitabine Sun, Capecitabine Teva, Capecitabine Medac, Capecitabine Accord, Ro 09-1978, capecitabina, capecitabinum, Capecitabin, Ecansya, Ro 09-1978/000, Pentyl (1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate, N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine, UNII-6804DJ8Z9U, Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate, 5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine, DTXSID3046451, CHEBI:31348, HSDB 7656, Ro-091978000, Cytidine, 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-, 6804DJ8Z9U, NSC-759853, (1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester, Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester, pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate, DTXCID1026451, RO-09-1978000, XELIRI COMPONENT CAPECITIBINE, Capecitabine [USAN:USP:INN:BAN], NSC 759853, Capecitabine [USAN], Ro-09-1978-000, Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate, CAPECITABINE (MART.), CAPECITABINE [MART.], pentyl 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-ylcarbamate, CAPECITABINE (USP-RS), CAPECITABINE [USP-RS], Cytidine, 5'-deoxy-5-fluoro-N-((pentyloxy)carbonyl)-, CAPECITABINE (EP MONOGRAPH), CAPECITABINE (USP IMPURITY), CAPECITABINE [EP MONOGRAPH], CAPECITABINE [USP IMPURITY], Capecitabine (USAN:USP:INN:BAN), CAPECITABINE (USP MONOGRAPH), CAPECITABINE [USP MONOGRAPH], Capecitabine (Xeloda), SMR002530052, Xeloda (TN), CAS-154361-50-9, R340, NSC712807, NCGC00164569-01, Pentyl (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate, Capecitabine 150mg, Capecitabine 500mg, RG-340, Capecitabine- Bio-X, Ro-09-1978, CAPECITABINE [MI], R-340, CAPECITABINE [INN], CAPECITABINE [JAN], CAPECITABINE [HSDB], Xelox component capecitabine, SCHEMBL8153, CAPECITABINE [VANDF], CHEMBL1773, MLS003915642, MLS004774137, pentyl N-{1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl}carbamate, CAPECITABINE [WHO-DD], Capecitabine (JAN/USP/INN), Capecitabine Tablets, 150 mg, Capecitabine Tablets, 500 mg, GTPL6799, CAPECITABINE [EMA EPAR], Capecitabine, analytical standard, Capecitabine, >=98% (HPLC), EX-A835, L01BC06, BCPP000300, CAPECITABINE [ORANGE BOOK], GLXC-03327, HY-B0016, Tox21_112198, s1156, AKOS015920130, Tox21_112198_1, AM84502, BCP9000483, BS-1000, CCG-264841, CS-0768, DB01101, NCGC00164569-02, NCGC00164569-05, NCGC00164569-11, BC164277, BP-58647, NS00000464, D01223, n4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine, AB01274776-01, AB01274776-02, AB01274776_04, 5'-deoxy-5-fluoro-N4-(pentyloxycarbonyl)cytidine, Q420207, SR-01000931255, 5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)-cytidine, J-700154, Q-200788, SR-01000931255-3, BRD-K61192372-001-08-9, Z1501480421, Capecitabine, European Pharmacopoeia (EP) Reference Standard, Capecitabine, United States Pharmacopeia (USP) Reference Standard, Capecitabine, Pharmaceutical Secondary Standard; Certified Reference Material, CARBAMIC ACID, (1-(5-DEOXY-.BETA.-D-RIBOFURANOSYL)-5-FLUORO-1,2-DIHYDRO-2-OXO-4-PYRIMIDINYL)-, PENTYL ESTER, PENTYL 1-(5-DEOXY-.BETA.-D-RIBOFURANOSYL)-5-FLUORO-1,2-DIHYDRO-2-OXO-4-PYRIMIDINECARBAMATE
Drug Type	Small molecule
Formula	C₁₅H₂₂FN₃O₆
SMILES	CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O
InChI	1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1
InChIKey	GAGWJHPBXLXJQN-UORFTKCHSA-N
CAS Number	154361-50-9
ChEMBL ID	CHEMBL1773
ChEBI ID	CHEBI:31348
TTD ID	D00HCQ
Drug Bank ID	DB01101
KEGG ID	D01223
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Hesperetin, Capecitabine
Partner Name	Hesperetin
Disease Info	[ICD-11: 2B90]	Colon cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Expression	IL4	hsa3565
	Up-regulation	Expression	IL4	hsa3565
	Down-regulation	Expression	MKI67	hsa4288
	Up-regulation	Expression	TP53	hsa7157
	Up-regulation	Expression	TP53	hsa7157
In Vivo Model	The current study was designed to evaluate the anti-carcinogenic effects of hesperetin (HES) alone and in combination with capecitabine (CAP) on 1,2 dimethylhydrazine (DMH)-induced colon carcinogenesis in Wistar rats. The rats were given DMH at 20 mg/kg body weight (b.w.)/week for 12 weeks and were orally treated with HES (25 mg/kg b.w.) and/or CAP (200 mg/kg b.w.) every other day for 8 weeks.
Result	It can be suggested that both HES and CAP, singly or in combination, have the potential to exert chemopreventive effects against DMH-induced colon carcinogenesis via the suppression of oxidative stress, the stimulation of the antioxidant defense system, the attenuation of inflammatory effects, the reduction in cell proliferation and the enhancement of apoptosis.

Pair Name	Gamma-Tocotrienol, Capecitabine
Partner Name	Gamma-Tocotrienol
Disease Info	[ICD-11: 2B91]	Colorectal cancer		Investigative
Gene Regulation	Down-regulation	Expression	BIRC2	hsa329
	Down-regulation	Expression	BIRC3	hsa330
	Down-regulation	Expression	BIRC5	hsa332
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Expression	CXCR4	hsa7852
	Down-regulation	Expression	ICAM1	hsa3383
	Down-regulation	Expression	MMP9	hsa4318
	Down-regulation	Expression	MYC	hsa4609
	Down-regulation	Expression	NFKB1	hsa4790
	Down-regulation	Expression	VEGFA	hsa7422
In Vitro Model	HCT 116	Colon carcinoma	Homo sapiens (Human)	CVCL_0291
In Vivo Model	Luciferase-transfected HCT 116 cells (2×10⁶) in PBS (50 μl) were injected subcutaneously into the leg of each mouse with a 27-gauge needle.
Result	Our findings suggest that γ-T3 inhibited the growth of human CRC and sensitised CRC to capecitabine by regulating proteins linked to tumourigenesis.

Pair Name	Gamma-Tocotrienol, Capecitabine
Partner Name	Gamma-Tocotrienol
Disease Info	[ICD-11: 2B72]	Gastric cancer		Investigative
Biological Phenomena	Inhibition-->Angiogenesis
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BCL-xL	hsa598
	Down-regulation	Expression	BIRC5	hsa332
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Expression	COX2	hsa4513
	Down-regulation	Expression	CXCR4	hsa7852
	Down-regulation	Expression	ICAM1	hsa3383
	Down-regulation	Expression	MMP9	hsa4318
	Up-regulation	Expression	PARP1	hsa142
	Down-regulation	Expression	RELA	hsa5970
	Down-regulation	Expression	VEGFA	hsa7422
	Down-regulation	Expression	XIAP	hsa331
In Vitro Model	SNU-5	Gastric adenocarcinoma	Homo sapiens (Human)	CVCL_0078
	SNU-16	Gastric adenocarcinoma	Homo sapiens (Human)	CVCL_0076
	MKN45	Gastric adenocarcinoma	Homo sapiens (Human)	CVCL_0434
Result	Our results show that γ-tocotrienol can potentiate the effects of capecitabine through suppression of NF-κB-regulated markers of proliferation, invasion, angiogenesis, and metastasis.

Pair Name	Dihydroartemisinin, Capecitabine
Partner Name	Dihydroartemisinin
Disease Info	[ICD-11: 2B91]	Colorectal cancer		Investigative
Gene Regulation	Down-regulation	Expression	CTNNB1	hsa1499
	Down-regulation	Expression	GSK3B	hsa2932
	Down-regulation	Expression	MKI67	hsa4288
	Down-regulation	Expression	MMP9	hsa4318
	Down-regulation	Expression	PECAM1	hsa5175
	Down-regulation	Expression	TCF7	hsa6932
In Vitro Model	HCT 116	Colon carcinoma	Homo sapiens (Human)	CVCL_0291
	DLD-1	Colon adenocarcinoma	Homo sapiens (Human)	CVCL_0248
	HCT 15	Colon adenocarcinoma	Homo sapiens (Human)	CVCL_0292
	SW620	Colon adenocarcinoma	Homo sapiens (Human)	CVCL_0547
	CT26	Mouse colon adenocarcinoma	Mus musculus (Mouse)	CVCL_7254
In Vivo Model	CT26 cells (8×10⁵) were injected into the tail vein of BALB/c mice to establish the lung metastasis model. HCT116 cells (2×106) were injected into the tail vein of BALB/c nude mice to establish the peritoneal metastasis model.
Result	DHA in combination with Cap could be a novel therapeutic strategy for CRC with improved efficacy and reduced side effects.